CannaPharmaRx, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenues of $656,606 for the three months ended September 30, 2025, a substantial increase from $312,164 in the same period last year. For the nine months ending September 30, 2025, total revenue reached $1,223,533, compared to $338,003 in the prior year. Despite this growth in revenue, the company reported a net loss of $1,477,811 for the quarter and a net loss of $3,581,863 for the nine-month period, reflecting ongoing challenges in managing costs associated with increased production and operational expenses.
The cost of goods sold (COGS) also rose significantly, totaling $1,096,606 for the third quarter of 2025, compared to $668,322 in the same quarter of 2024. This increase was attributed to higher sales volumes and associated production costs, including direct materials and labor. The gross loss for the quarter was $440,000, up from $356,158 in the previous year, indicating that while revenue increased, the costs associated with generating that revenue rose at a faster rate.
Strategically, CannaPharmaRx has been focusing on expanding its operations and product offerings. The company has entered into a security and royalty agreement with Koze Investments LLC, which requires the company to pay a royalty on cannabis product sales. This agreement, along with the onboarding of new retail partners, is expected to enhance the company's market presence, particularly in the European markets. Additionally, the company is working towards increasing its cultivation capacity at its facility in Alberta, Canada, with plans to operate all ten growing rooms in the near future.
Operationally, CannaPharmaRx has faced challenges, including a working capital deficiency of $27,009,769 as of September 30, 2025, compared to $24,733,636 at the end of 2024. The company reported cash of only $927, down from $2,156 at the end of the previous fiscal year. The increase in liabilities, particularly related party loans and accrued interest, has raised concerns about the company's liquidity and ability to continue operations without additional financing. The company is actively seeking to raise capital through equity financing and related party transactions to address these financial challenges.
Looking ahead, CannaPharmaRx's management has expressed substantial doubt about the company's ability to continue as a going concern, given its current financial position and reliance on related party transactions for funding. The company is focused on executing its growth strategy, which includes expanding its product lines and improving distribution capabilities, but acknowledges that its success will depend on securing additional capital and effectively managing its operational costs.
About CANNAPHARMARX, INC.
CannaPharmaRx, Inc. operates licensed cannabis cultivation and processing facilities in Canada, producing high-quality dried medical cannabis flower. The company focuses on indoor cultivation under strict regulatory standards, targeting medical and recreational cannabis markets primarily in Canada, with plans to serve European and Israeli markets. Its business model centers on compliant production, quality control, and distribution of cannabis products, leveraging licenses and certifications to meet evolving regulatory requirements.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.